GBLX - GB Sciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1963
-0.0043 (-2.14%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.2006
Open0.0000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume1,481,904
Market Cap43.579M
Beta (3Y Monthly)-0.54
PE Ratio (TTM)N/A
EPS (TTM)-0.1920
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit
    PR Newswire1 hour ago

    Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit

    Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia". LAS ...

  • GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases
    PR Newswire4 days ago

    GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Diseases

    LAS VEGAS, Dec. 7, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State University Agricultural Center, entered into a Master Research and Development Agreement with GB Sciences Louisiana, LLC. The Master Research and Development Agreement comes from the parties' desire to participate in joint research and development projects arising out of the production of therapeutic cannabis in Louisiana. As a public institution of higher education, the LSU AgCenter's public-private partnership with GB Sciences Louisiana represents a first in the therapeutic cannabis industry.

  • GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor
    PR Newswire14 days ago

    GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor

    Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure. LAS VEGAS, Nov. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai Biotechnology, LLC, Dr. Alexander Stokes, and researchers from the University of Kyoto, Japan.

  • GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
    PR Newswire21 days ago

    GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles

    LAS VEGAS, Nov. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain. "We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain," said Dr. Andrea Small-Howard.

  • More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD
    PR Newswire27 days ago

    More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.

  • GB Sciences Expands into the Oklahoma Medical Cannabis Market
    PR Newswire27 days ago

    GB Sciences Expands into the Oklahoma Medical Cannabis Market

    LAS VEGAS, Nov. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma.  This company has been awarded cultivation, processing and dispensary licenses by the Oklahoma Medical Marijuana Authority. Under their agreement, GB Sciences will design a cultivation and processing facility in Oklahoma, and provide 4EVERGRN with best-practice operating procedures. 4EVERGRN will produce and distribute GB Sciences products and brands under a licensing agreement in exchange for a royalty to GB Sciences.  The agreement can be terminated if quality standards are abridged or compromised.

  • Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD
    PR Newswirelast month

    Meredith Patterson, GB Sciences' Brain Nurse, Examines the Workings of CBD

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Nov. 6, 2018 /PR Newswire/-- GB Sciences, Inc. (GBLX) offers a series of blogs by "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has always paid close attention to her patients.

  • GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium
    PR Newswirelast month

    GB Sciences Sponsors "2018 Innovation In Medical Cannabis Therapies" Symposium

    On November 9th, an international medical cannabis symposium, led by Dr. Andrea Small-Howard, will be held in Las Vegas, NV. LAS VEGAS, Nov. 1, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces sponsorship of a one day, November 9th, international medical cannabis symposium, "Innovation in Medical Cannabis Therapies", under the direction of Dr. Andrea Small-Howard, Chief Science Officer and a member of the Board of Directors for GB Sciences.

  • GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis
    PR Newswire2 months ago

    GB Sciences' Brain Nurse Explores the New and Exciting World of Medical Cannabis

    Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis blogs for GB Sciences. LAS VEGAS, Oct. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) introduces "the brain nurse", Meredith Patterson RN, BSN, CRRN.  In her over 25yrs of experience in neuroscience nursing, Meredith has learned the value of questions.  When she first heard patients extolling the virtues of cannabis for serious medical conditions, such as Parkinson's as well as difficult to treat ongoing conditions such as chronic pain, she got curious.

  • GB Sciences Harvests the First Hemp Crop in Colorado
    PR Newswire2 months ago

    GB Sciences Harvests the First Hemp Crop in Colorado

    Harvesting the first crop, in association with the Colorado Hemp Project, GB Sciences explores hemp as a highly reliable source of hard to find cannabinoids and terpenes for cannabis-based medical formulations as well as a fresh source of revenue from the sale of hemp oil and related products. LAS VEGAS, Oct. 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces the harvesting of its first hemp crop in association with the Colorado Hemp Project. Following closely on the overall philosophy and strategy of the Company, hemp is planned to provide both a reliable source of hard to find cannabinoids and terpenes necessary to manufacture cannabis-based medical formulations and also provide a fresh revenue source through the sale of bulk hemp oil and other hemp related products.

  • GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles
    PR Newswire2 months ago

    GB Sciences' CEO John Poss and Chief Science Officer Dr. Andrea Small-Howard Featured at Digital Hollywood's California Cannabis Forum in Los Angeles

    Mr. Poss will speak on GB Sciences' collaboration with Native Americans in California; Dr. Small-Howard will discuss research to address specific diseases using cannabinoids. LAS VEGAS , Oct. 10, 2018 ...

  • GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018
    PR Newswire2 months ago

    GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018

    LAS VEGAS, Oct. 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th. According to the conference organizers, "CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world's top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis.

  • GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds
    PR Newswire2 months ago

    GB Sciences and University of Athens, Greece, Embark on Next-Level Drug Discovery Examining Cannabis-Based, Disease-Modifying Compounds

    GB Sciences explores the therapeutic potential of the chemical diversity within different varieties of the cannabis plant to make better medicine for patients worldwide. LAS VEGAS, Oct. 3, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) initiates a new project with the Department of Pharmacognosy and Natural Products Chemistry at the National Kapodistrian University of Athens, Greece.  Titled: The Cannabis Metabolomics ("Canna-bolomics") Project, the program will analyze each of GB Sciences' cultivars to determine whether additional molecules in these cultivars, and hundreds of other natural cannabis and hemp cultivars, show significant promise to treat diseases. "GB Sciences is widening the lens with which we observe and characterize plant-based, cannabis-derived chemical mixtures for human therapies starting from GB Sciences' stock genotypes.

  • PR Newswire2 months ago

    GB Sciences' Drug Development Program Benefits from Establishment of Clear Pathway for Cannabis-Based Drug Approvals and Commercialization

    LAS VEGAS, Oct. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has gained momentum in its innovative drug discovery program with the Drug Enforcement Administration (DEA)'s decision to reschedule GW Pharmaceuticals' Epidiolex, from Schedule I to Schedule V of the Controlled Substances Act (CSA).  In June of 2018, Epidiolex was the first ever plant-based, cannabis drug to be approved by the Food and Drug Administration (FDA). There is now both a regulatory precedent for market approval on a plant-based cannabinoid-containing drug and a path to its commercialization.

  • Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies
    PR Newswire2 months ago

    Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies

    GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson's disease SWINDON, U.K. , and LAS VEGAS , Sept. 26, ...

  • GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals
    PR Newswire3 months ago

    GB Sciences Granted a Recreational Production License for the Manufacture of Oils, Edibles, Vape Products, and Nutraceuticals

    The new license provides access to the largest growing sectors in the cannabis industry. Multiple new brands for both medical and recreational markets being prepped for retail sales. LAS VEGAS, Sept. 25, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has been granted a recreational production license for the manufacture of cannabis oils.  Oils are the base ingredient for vape products, tinctures, edibles, and nutraceutical formulations.

  • GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"
    PR Newswire3 months ago

    GB Sciences Hosts Cutting-Edge Cannabis Symposium "Innovation in Medical Cannabis Therapies"

    LAS VEGAS, Sept. 20, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX)  has mobilized cannabis industry thought leaders to discuss both the immense potential for cannabis-based therapies and the challenges of delivering on their medical promise under state regulated programs at their fourth annual "Innovation in Medical Cannabis Therapies" symposium on November 9th at the "Keep Memory Alive" Event Center at the Cleveland Clinic's Lou Ruvo Center for Brain Health in Las Vegas, NV. This event has attracted innovative leaders in cannabis biotech, nanotech, metabolomics, cultivation and extraction tech.  GB Sciences is pleased to announce this will include representatives from US and international research universities, cannabis industry leaders, clinical research organizations, and cannabis tech companies.

  • GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary
    PR Newswire3 months ago

    GB Sciences' Dr. Andrea Small-Howard, Chief Science Officer, Will Be Moderating a Panel Discussion in "Cannabis Is Medicine" at the "State of Cannabis" Conference on the Queen Mary

    Dr. Andrea Small-Howard is featured in the "Meeting of the Minds" at the two-day educational conference hosted on the historic Queen Mary. LAS VEGAS, Sept. 18, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announces that Dr. Andrea Small-Howard will be moderating the panel discussion which kicks-off the "Cannabis Is Medicine Track" and explores important Research Initiatives. Of great interest to this panel is The Medical Cannabis Research Act of 2018, which was unanimously approved by the House Judiciary Committee with widespread bipartisan support on September 13th.

  • The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership
    PR Newswire4 months ago

    The State of Louisiana Pharmacy Board Has Selected Nine Initial Pharmacies to Dispense Medical Cannabis Formulations Through the GB Sciences and LSU Agriculture Center Partnership

    In Partnership with GB Sciences and LSU AgCenter, Nine Select Louisiana Pharmacies Are Set to Pioneer the Louisiana Medical Cannabis Program. BATON ROUGE, La. , Aug. 23, 2018 /PRNewswire/ -- GB Sciences, ...

  • GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop
    PR Newswire4 months ago

    GB Sciences and Louisiana State University Agricultural Center Begins Cultivation of Their First Cannabis Crop

    The first plants generated through tissue culture have now moved into their environmentally controlled cannabis grow pod. BATON ROUGE, La., Aug. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and the LSU Agricultural Center (LSU AgCenter), have now commenced operation in the environmentally controlled grow pod. Representatives from nine Louisiana pharmacies authorized to dispense medical cannabis toured our high-tech 36,000-sq ft GB Sciences facility in Baton Rouge, LA.

  • Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease
    PR Newswire4 months ago

    Michigan State University's Dr. Norbert Kaminski Begins Pre-Clinical Study of GB Sciences' Neuroprotective Cannabis Compounds For Parkinson's Disease

    This pre-clinical study examines the Immunotoxicology and anti-inflammatory properties of GB Sciences' Cannabis-Containing Complex Formulas for Parkinson's Disease in preparation for their clinical trial. LAS VEGAS, Aug. 6, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has signed an agreement to initiate research collaborations with Dr. Norbert Kaminski, Professor of Pharmacology & Toxicology at Michigan State University. Dr. Kaminski will study the toxicology, anti-inflammatory properties, and immunomodulatory activity of GB Sciences' proprietary cannabis-based neuroprotective compounds using a diverse array of assays employing human primary white blood cells.

  • GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"
    PR Newswire4 months ago

    GB Sciences Co-Authors a Peer Reviewed Article Published in the Journal of the American Heart Association Titled: "Cannabinoids, The Heart of the Matter"

    This pioneering research article explains the benefits of cannabinoid-based medicines for heart disease therapies based on scientific research. LAS VEGAS, Aug. 2, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce the publication of a review article co-authored by GB Sciences and key collaborators in the Journal of the American Heart Association, which explains the potential medical benefits of using cannabinoid-based therapies for the treatment of heart diseases. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including Dr. Alexander Stokes, President of Makai Biotechnology, LLC, and Dr. Helen Turner, VP of Innovation and Dean of the Division of Natural Sciences and Mathematics at Chaminade University, in expounding on this very important subject in "Cannabinoids, the Heart of the Matter".

  • GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market
    PR Newswire5 months ago

    GB Sciences Partners with the Colorado Hemp Project to Cultivate and Extract Full Spectrum Hemp Oil from Proprietary Hemp Strains to Open a New Revenue Stream in the Rapidly Growing Hemp Market

    The first six proprietary strains are being cultivated by The Colorado Hemp Project and will serve as the basis for fresh revenue streams from both retail sales and raw ingredients for cannabis-based medical formulations. LAS VEGAS, July 16, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) updates the progress in their efforts to identify, cultivate and extract full spectrum hemp oil from proprietary hemp strains that contain desirable ratios of CBD, cannabinoids and terpenes to provide the necessary compounds to support both the Company's medical Intellectual Properties portfolio and open a fresh revenue stream in the rapidly growing retail hemp market. The search for a full spectrum hemp oil product that matched the quality and consistency of their cannabis genetics led GB Sciences to The Colorado Hemp Project.